A pharmacokinetic drug–drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects

A pharmacokinetic drug–drug interaction study between selexipag and midazolam, a CYP3A4... Eur J Clin Pharmacol (2017) 73:1121–1128 DOI 10.1007/s00228-017-2282-7 PHARMACOKINETICS AND DISPOSITION A pharmacokinetic drug–drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects 1 1 2 1 Pierre-Eric Juif & Margaux Boehler & Yves Donazzolo & Shirin Bruderer & Jasper Dingemanse Received: 28 April 2017 /Accepted: 7 June 2017 /Published online: 21 June 2017 Springer-Verlag GmbH Germany 2017 Abstract treatment B compared to A for both midazolam (16%) and Purpose In vitro data showed that selexipag and its active 1-hydroxymidazolam (20%). Exposure (area under the curve) metabolite (ACT-333679) have an inductive effect on to midazolam and 1-hydroxymidazolam was similar between CYP3A4, CYP2B6, and CYP2C9 at concentrations approxi- treatments, and the 90% confidence intervals of geometric mately 100-fold higher than the maximum plasma concentra- mean ratios were within the bioequivalence interval. tion (C ) measured under steady-state conditions. In order Treatment with midazolam, selexipag, and the combination max to confirm in vivo the lack of induction at the enterocyte level, was safe and well tolerated. we assessed the effect of selexipag on midazolam, a substrate Conclusion Exposure to midazolam and 1-hydroxymidazolam of hepatic and intestinal CYP3A4. was not affected by treatment with selexipag. Methods This study http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Pharmacology Springer Journals

A pharmacokinetic drug–drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects

Loading next page...
 
/lp/springer_journal/a-pharmacokinetic-drug-drug-interaction-study-between-selexipag-and-nhiOFsPfQs
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany
Subject
Biomedicine; Pharmacology/Toxicology
ISSN
0031-6970
eISSN
1432-1041
D.O.I.
10.1007/s00228-017-2282-7
Publisher site
See Article on Publisher Site

Abstract

Eur J Clin Pharmacol (2017) 73:1121–1128 DOI 10.1007/s00228-017-2282-7 PHARMACOKINETICS AND DISPOSITION A pharmacokinetic drug–drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects 1 1 2 1 Pierre-Eric Juif & Margaux Boehler & Yves Donazzolo & Shirin Bruderer & Jasper Dingemanse Received: 28 April 2017 /Accepted: 7 June 2017 /Published online: 21 June 2017 Springer-Verlag GmbH Germany 2017 Abstract treatment B compared to A for both midazolam (16%) and Purpose In vitro data showed that selexipag and its active 1-hydroxymidazolam (20%). Exposure (area under the curve) metabolite (ACT-333679) have an inductive effect on to midazolam and 1-hydroxymidazolam was similar between CYP3A4, CYP2B6, and CYP2C9 at concentrations approxi- treatments, and the 90% confidence intervals of geometric mately 100-fold higher than the maximum plasma concentra- mean ratios were within the bioequivalence interval. tion (C ) measured under steady-state conditions. In order Treatment with midazolam, selexipag, and the combination max to confirm in vivo the lack of induction at the enterocyte level, was safe and well tolerated. we assessed the effect of selexipag on midazolam, a substrate Conclusion Exposure to midazolam and 1-hydroxymidazolam of hepatic and intestinal CYP3A4. was not affected by treatment with selexipag. Methods This study

Journal

European Journal of Clinical PharmacologySpringer Journals

Published: Jun 21, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off